Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (1068)	3/3/2000 11:15:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

OT Gliatech We could debate Gliatech, but it would not be half as entertaining than the war waged on Yahoo--which I encourage folks to check out. GLIA will double before Ariad doubles again. It is time. Something is going to happen. Something wonderful. <grin> This should strike you right at your 'core' Actually my core position is Cambridge Neuroscience, CNSI. They licensed to Creative BioMolecules GDF-1 but kept the neuregulin GGF2 for themselves. Now why do you suppose they did that? Hit google and do a query for GGF2. google.com Or visit their website cambneuro.com Or freak out when you see how they loaded up recap: recap.com And look into 5161. CNSI will triple before Ariad doubles again. --Mike.twocents.biotech.Jedi